Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Company profile
Ticker
GLPG, GLPGF
Exchange
Website
CEO
Paul Stoffels
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
GLPG stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Galapagos announces full year 2023 results and outlook for 2024
23 Feb 24
6-K
Galapagos presents at EBMT-EHA annual meeting 2024
16 Feb 24
6-K
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6 Feb 24
6-K
Current report (foreign)
4 Jan 24
6-K
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4 Jan 24
6-K
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4 Jan 24
6-K
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
21 Dec 23
6-K
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
12 Dec 23
6-K
Current report (foreign)
12 Dec 23
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
EcoR1 Capital, LLC
7 Jun 23
SC 13G/A
EcoR1 Capital, LLC
14 Feb 23
SC 13G
FMR LLC
9 Feb 23
SC 13G
EcoR1 Capital, LLC
3 Feb 22
SC 13D
VAN HERK INVESTMENTS B.V.
2 Nov 21
SC 13G/A
Capital International Investors
10 May 21
SC 13G/A
Capital International Investors
10 Feb 21
SC 13G
Capital International Investors
10 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
67.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 75 |
Opened positions | 6 |
Closed positions | 10 |
Increased positions | 32 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 660.21 bn |
Total shares | 44.32 mm |
Total puts | 73.20 k |
Total calls | 90.20 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
GILD Gilead Sciences | 20.63 mm | $3.20 bn |
EcoR1 Capital | 5.76 mm | $198.88 bn |
Van Herk Investments B.V. | 4.64 mm | $0.00 |
FMR | 4.32 mm | $149.18 bn |
BVF | 1.92 mm | $66.17 bn |
Stonepine Capital Management | 802.54 k | $27.73 bn |
Segall Bryant & Hamill | 737.99 k | $25.50 bn |
Prosight Management | 730.21 k | $25.23 bn |
Primecap Management | 669.68 k | $23.14 bn |
Wellington Management | 476.67 k | $16.47 bn |
News
B of A Securities Downgrades Galapagos to Underperform, Lowers Price Target to $31
28 Mar 24
Morgan Stanley Assumes Galapagos at Equal-Weight, Announces Price Target of $38
7 Mar 24
Earnings Scheduled For February 22, 2024
22 Feb 24
Galapagos To Present New Preliminary Translational Data And Previously Disclosed Data From EUPLAGIA-1 Phase 1/2 Study At The European Society For Blood And Marrow Transplantation - 8K
16 Feb 24
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
3 Jan 24
Press releases
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
26 Mar 24
Galapagos announces full year 2023 results and outlook for 2024
22 Feb 24
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
15 Feb 24
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
5 Feb 24